The European Society of Cardiology 2024 Guidelines on Chronic Coronary Syndromes: A Critical Appraisal
Journal of Clinical Medicine · 2025 · Europe
Source and licence
- Authors
- Roberto Ferrari, Luis Henrique W. Gowdak, Francisco Padilla et al.
- Title
- The European Society of Cardiology 2024 Guidelines on Chronic Coronary Syndromes: A Critical Appraisal
- Journal
- Journal of Clinical Medicine, 2025
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC11856662
Licence statement of the original publication
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
This is a review of another guideline (2024 ESC Guidelines for the management of chronic coronary syndromes, ESC 2024). We do not reproduce that guideline's recommendations here – they belong to the original guideline.
Open the original publication →Full text on Europe PMC
Abstract
Background: During the 2024 annual meeting in London, The European Society of Cardiology released new guidelines (GLs) on chronic coronary syndromes (CCSs) and simultaneously published them in the European Heart Journal. Method: A few experts on the topic from Europe, South America, India, and Asia, who attended the presentation and the Question and Answer sections, met virtually to comment on the GLs after carefully reading the 123-page document. Result: There is a consensus that the presented GLs are a comprehensive, up-to-date, clear document of the available data on how to diagnose and treat CCSs and a definite step forward compared to all previous GLs. Of particular value are (a) the efforts to link both diagnosis and treatment to the underlying pathophysiology with the recognition that not all the ischaemic episodes are the same; (b) the decision to adopt the graphic of the so-called “Diamond Approach”, although its spirit that no antianginal drug is superior to another is not fully adopted; and (c) the innovative way it condenses and expresses the relevant messages with eye-catching illustrations. Conclusions: The present article summarises and comments on the 123-page GLs, highlighting strengths and weaknesses according to the thoughts of the authors.
Contents of the original publication
The section headings of the original.
- 1. Introduction
- 2. Preamble to the ESC Guidelines
- 3. Diagnosis
- 4. Therapy
- 5. Myocardial Revascularisation in Patients with CCS
- 6. Treatment of Specific Groups of Patients
- 7. Conclusions
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint